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a  b  s  t  r  a  c  t
Candida species, especially C. albicans, are commensals on human mucosal surfaces, but are
increasingly becoming one of the important invasive pathogens as seen by a rise in its preva-
lence  in immunocompromised patients and in antibiotic consumption. Thus, an accurate
identiﬁcation of Candida species in patients with pulmonary symptoms can provide impor-
tant information for effective treatment. A total of 75 clinical isolates of Candida species
were obtained from the bronchoalveolar lavage ﬂuid of both immunocompromised and
immunocompetent patients with pulmonary symptoms. Candida cultures were identiﬁed
based on nuclear ribosomal Internal Transcribed Spacer (ITS1-ITS2 rDNA) sequence anal-
ysis by polymerase chain reaction–restriction fragment length polymorphisms (PCR-RFLP).
Molecular identiﬁcation indicated that the isolates belonged predominantly to C. albicans
(52%), followed by C. tropicalis (24%), C. glabrata (14.7%), C. krusei (5.3%), C. parapsilosis (1.3%),
C.  kefyr (1.3%) and C. guilliermondii (1.3%). Given the increasing complexity of disease proﬁles
and  their management regimens in diverse patients, rapid and accurate identiﬁcation of
Candida species can lead to timely and appropriate antifungal therapy.©  2015 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
an open access article under the CC BY-NC-ND license∗ Corresponding author at: Department of Medical Parasitology and Myc
Isfahan, Iran.
E-mail: dr.rasoul mohammadi@yahoo.com (R. Mohammadi).
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ntroduction
andida spp. are the causative agents in 80% of nosocomial
ungal infections.1 They are frequently isolated from respi-
atory secretions in mechanically ventilated patients due to
ither seeding of the lungs during hematogenous dissemina-
ion, or aspiration of previously colonized oropharyngeal or
astric contents.2 Although the isolation of Candida spp. from
he bronchoalveolar lavage (BAL) ﬂuid of immunocompetent
ndividuals is not an indication for treatment,3 nevertheless,
4% of all intensive care physicians prescribe antifungal ther-
py in immunocompetent, mechanically ventilated patients
esting positive for Candida spp.4 Although the accuracy of
racheal surveillance cultures is controversial, the absence of
andida spp. in these cultures has a high negative predictive
alue for disseminated candidiasis in patients with leukemia,
ymphoma, or those who  have undergone bone marrow
ransplantation.2 Rapid identiﬁcation of Candida infections
an, therefore, help in prompt and appropriate antifungal
herapy. However, the diagnosis of pulmonary candidiasis is
till controversial,5 and the detection of primary fungal lung
nfection requires a lung biopsy.6 However, in routine clinical
ractice, lung biopsies cannot be used for the management of
atients with suspected Candida infection.7
Although C. albicans is the most frequently isolated
athogen,8 an increase in the incidence of infections due to
ther isolates, including C. tropicalis, C. glabrata, C. krusei,  and
. parapsilosis, which are the cause of opportunistic infec-
ion oropharyngeal candidiasis (OPC), has been reported.9
n recent decades, C. glabrata, which is resistant to ﬂucona-
ole, has emerged as the second most common causative
rganism (10–30% of all yeast isolates) of mucosal and inva-
ive fungal infections,10 trailing only C. albicans (50–60%). A
arge multicenter study showed an increase in the occur-
ence of C. glabrata infections from 14% in 1993 to 24% in
998.10 The reasons for this increase have been investigated,
nd include shifts in the distribution of infections by certain
andida spp. and along with both endogenous and exoge-
ous reservoirs.11 Therefore, an accurate identiﬁcation of the
ausative Candida spp. in patients with pulmonary symptoms,
articularly in immunocompromised individuals, will enable
roper diagnosis and effective treatment, apart from broaden-
ng the physicians’ knowledge of the epidemiology of Candida
pp.5,12,13 Thus, this study aims to accurately identify and
uantify the prevalence of Candida spp. present in the BAL
uid of both immunocompromised and immunocompetent
atients with pulmonary disorders such as pulmonary can-
idiasis or colonization.
aterials  and  methods
pecimens  and  preparation
uring a 16-month period, 75 BAL ﬂuid specimens were
btained from both immunocompromised and immunocom-
etent patients with pulmonary disorders who were referred
o the Shariati Hospital, Tehran, Iran for bronchoscopy. BAL
pecimens were submitted to the Medical Mycology laboratory
t the School of Public Health, Tehran University of Medicalo l o g y 4 7 (2 0 1 6) 172–176 173
Sciences, Tehran, Iran. The BAL ﬂuid specimens, requested
and obtained by a specialist physician, were collected in sterile
vessels without any conservative media and transferred to the
laboratory. The starting volume of BAL ﬂuid ranged between 4
and 7 mL.  Specimens were centrifuged at 3000 rpm for 20 min,
pellet vortexed and resuspended in a small volume of super-
natant (total 0.5–1 mL).14
A 150 L aliquot of the sediment was mixed with a drop
of 20% potassium hydroxide (KOH) on a microscopic slide,
covered with a large sterile coverslip (24 mm × 50 mm)  and
viewed under 100× and 400× magniﬁcations. The aliquots of
the specimens (75 L) were plated on both 4% Sabouraud glu-
cose agar (SGA) (Difco, USA) and Brain Heart Infusion agar (BHI)
(Difco, USA).15 Plates were incubated for 2–4 days at 30 ◦C and
monitored for growth of yeast colonies. Colony isolates were
suspended in sterile distilled water and kept at −4 ◦C until
DNA extraction.
DNA  extraction  and  molecular  studies
To extract genomic DNA from the yeast colonies, FTA® Elute
MicroCards (Whatman Inc., Clifton, NJ, USA) were used16
according to manufacturer’s instructions but with minor mod-
iﬁcations as described by Mohammadi et al.17 The extracted
DNA samples were stored at −20 ◦C until use. Quality con-
trol was ensured by adding 18 reference strains of medically
important yeasts to the dataset, supplied by the Teikyo Uni-
versity Institute of Medical Mycology (TIMM), Tokyo, Japan.
The reference strains used were C. tropicalis (ATCC 750), C.
albicans (TIMM 1768), C. glabrata (ATCC 90030), C. parapsilo-
sis (ATCC 22019), C. nivariensis (CBS 10161), C. bracarensis (CBS
10154), C. krusei (ATCC 6258), C. orthopsilosis, C. metapsilosis, C.
guilliermondii (TIMM 3400), C. lusitaniae (TIMM 3479), C. famata
(JCM 1439), C. kefyr (TIMM 0300), Cryptococcus neoformans (ATCC
90113), C. norvegensis (JCM 2309), C. inconspicua (JCM 9555), C.
lusitaniae (TIMM 3479), C. intermedia (JCM 1607), C. rugosa (JCM
1619), C. viswanathii (JCM 9567), Saccharomyces cerevisiae (ATCC
9763).
In addition, DNASIS software (Hitachi Software Engineer-
ing Co., Ltd, Tokyo, Japan) was used to analyze GenBank
sequences of different yeasts to determine the size of the
entire ITS1-5.8SrDNAITS2 region before and after in silico
digestion with the Msp  I restriction enzyme,17 and molecu-
lar identiﬁcation was performed based on PCR-RFLP proﬁles
as described previously.17–19 Brieﬂy, the region was ampliﬁed
using a PCR mixture containing 5 L of the 10× reaction buffer,
1.5 mM MgCl2, 0.4 mM dNTPs, 2.5 U of DNA Taq polymerase,
30 pmol of each ITS1 (5′-TCC GTA GGT GAA CCT GCG G-3′) and
ITS4 (5′-TCC TCC GCT TAT TGA TAT GC-3′) primers and 3 L
of extracted DNA, in a ﬁnal volume of 50 L. The PCR condi-
tions were as follows: initial denaturation at 94 ◦C for 5 min,
followed by 35 cycles of denaturation at 94 ◦C for 30 s, anneal-
ing at 55 ◦C for 45 s, extension at 72 ◦C for 1 min, with a ﬁnal
extension step at 72 ◦C for 7 min. An aliquot of 10 L of each
PCR product was digested with the restriction enzyme Msp I
(Fermentas, Vilnius, Lithuania), and 12 L of each RFLP product
was fractionated by electrophoresis.
To conﬁrm the validity of the molecular results for
identiﬁcation of common Candida spp., some isolates includ-
ing C. albicans, C. glabrata, C. krusei and C. tropicalis were
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subcultured on CHROMagar Candida (CHROMagar Microbiol-
ogy, Paris, France) and incubated at 35 ◦C for 2–3 days.
Results
Seventy ﬁve isolates were obtained from BAL specimens of
32 immunocompromised and 43 immunocompetent patients.
The immunocompromised patient proﬁle included solid-
organ cancers (n = 8), intensive care units (ICU) patients (n = 8),
autoimmune conditions requiring corticosteroids (n = 7), solid
organ transplant recipients (n = 6), bone marrow transplant
recipients (n = 3).
Among these patients, 61% were male (n = 46) with an aver-
age age of 58.3 ± 17.6 years, and 39% were female (n = 29) with
an average age of 50.5 ± 19.8 years. The immunocompetent
patients had signiﬁcant history of respiratory disorders such
as cough, dyspnea, chest pain, hemoptysis, bronchial asthma,
and the presence of a cavity within an area of consolidation on
computerized tomography (CT) imaging. Table 1 summarizes
the demographic characteristics of the patients.
Pseudohyphae were seen in 38 specimens and yeast forms
were seen in 37 specimens upon direct microscopic examina-
tion.
The primer pairs (ITS1 and ITS2) were able to amplify the
ITS region and provided a single PCR product. Isolates were
identiﬁed using a combination of ITS-RFLP with MspI and the
ITS-amplicon size as previously established.17
Seven Candida species, including C. albicans (52%, n = 39), C.
tropicalis (24%, n = 18), C. glabrata (14.7%, n = 11), C. krusei (5.3%,
n = 4), C. parapsilosis (1.3%, n = 1), C. kefyr (1.3%, n = 1) and C.
guilliermondii (1.3%, n = 1) were identiﬁed (Table 1).
Importantly, the results of species identiﬁcation using
CHROMagar Candida for selected Candida isolates concurred
with those of the PCR-RFLP.
Discussion
Seventy-ﬁve Candida-positive isolates were obtained from
immunocompromised and immunocompetent patients with
pulmonary disorders and identiﬁed using PCR-RFLP. In recent
decades, the prevalence of Candida infections has increased,
particularly in immunocompromised patients. The incidence
of Candida pneumonia varies in different studies, and ranges
between 0.23% and 4.5%.20,21 Although Candida spp. are fre-
quently isolated from respiratory secretions of mechanically
ventilated patients, its presence in respiratory specimens only
represents colonization of the tracheobronchial tree, and the
criteria for the diagnosis of pulmonary candidiasis are still
controversial. In addition, the value of quantitative cultures
of respiratory samples in diagnosing Candida pneumonia is
unknown,5 since this study had two limitations: low speci-
men  number for evaluation of Candida prevalence and lack of
histologic ﬁndings consistent with pulmonary candidiasis.
The potential clinical importance of species-level identiﬁ-
cation for Candida infections has been recognized as individual
species difference in the expression of putative virulence
factors and antifungal susceptibility.22,23 In addition, rapid
identiﬁcation of Candida spp. can also lead to early and effec-
tive antifungal therapy, given the increasing rate at which
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rug-resistant Candida spp. are being reported.24,25 However,
ost yeast isolates obtained from patients with pulmonary
isorders, especially from immunocompromised patients, can
e identiﬁed to the species-level to reduce antifungal resis-
ance among the Candida spp., and associated morbidity and
ortality in these patients. Traditional diagnostic methods
uch as direct examination and culture are not sufﬁcient for
he identiﬁcation of yeast isolates, and in this study, pseu-
ohyphae and yeast forms were seen in different species
pon direct microscopy examination, without any signiﬁcant
elationship between species identity and morphology. An
xception to this observation is C. glabrata which has only
he yeast form. Further, fungal cultures could not differen-
iate between the Candida species, while all isolates could be
uccessfully identiﬁed using PCR-RFLP.
The results of the present study conﬁrm that PCR-RFLP
elps in the presumptive identiﬁcation of C. albicans, C. trop-
calis, C. glabrata, C. krusei,  C. parapsilosis, C. kefyr and C.
uilliermondii, and are similar to other reports.17–19,26 Although
e report a C. albicans prevalence of 52%, it is less than
he reported value in other studies (70–80%).27,28 This could
e because, over the last 10–30 years, non-C. albicans Can-
ida (NCAC) species have emerged as important opportunistic
athogens in humans, due to improved diagnostic methods,
ltered medical practices, differences in patient groups or geo-
raphic location.28 Compared to other studies, we show higher
ncidence of C. tropicalis (24%) and C. glabrata (14.7%) and lower
ncidence of C. parapsilosis and C. kefyr,17,29 while that of C.
uilliermondii (1.3%) was similar.17,30
The intriguing observation in our study was the dif-
erence in the distribution of the Candida spp. among
he immunocompromised and immunocompetent patients:
mmunocompetent patients showed higher incidence of C.
ropicalis, C. krusei, C. kefyr and C. albicans and a lower incidence
f C. parapsilosis and C. guilliermondii, compared to immuno-
ompromised patients.
Thus, this study highlights that, Candida isolates can be
uccessfully identiﬁed through PCR-RFLP and that such iden-
iﬁcation is important to show variation in the prevalence of
andida spp. among different patient groups, especially high
isk patients with signs of clinical deterioration.
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